ArticleThe European respiratory journal2019
The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.
Open access · hybridAbstract read
In one paragraph
Article in The European respiratory journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- ADAM and ADAMTS proteases as integrative hubs in heart failure pathogenesis and therapy.iScience · 2026Review
- Chronic Thromboembolic Pulmonary Hypertension as an Inflammation-Angiogenesis Disorder: From Thrombus Persistence to Dual Pulmonary Vasculopathy.Reviews in cardiovascular medicine · 2026Review
- Microbiome Dysregulation and Inflammation: Key Players in Pulmonary Hypertension Pathophysiology.Biomedicines · 2025Article
- Can Plasma ADAMTS13 Differentiate Patients With Pulmonary Arterial Hypertension From Other Forms of Pulmonary Hypertension and Dyspnea Control Patients.CHEST pulmonary · 2025Article
- The Role of the Pulmonary Vascular Microenvironment in Chronic Thromboembolic Pulmonary Hypertension.Pulmonary circulation · 2025Review
- Rare variants inERJ open research · 2025Article
- The Role of the VWF/ADAMTS13 Axis in the Thromboinflammatory Response in Ischemic Stroke After SARS-CoV2 Infection.Brain and behavior · 2025Article
- Angiopoietin-2 and D-dimer add prognostic information to clinical risk in pulmonary arterial hypertension.JHLT open · 2025Article
- Genetic patterns related to von Willebrand factor: implications on the need for mechanical ventilation, severity, and death in COVID-19.Frontiers in medicine · 2025Article
- From Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension: A Pathophysiological Approach.Reviews in cardiovascular medicine · 2024Review
- An exploration into CTEPH medications: Combining natural language processing, embedding learning, in vitro models, and real-world evidence for drug repurposing.PLoS computational biology · 2024Article
- Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13.Scientific reports · 2024Article
- Chronic Thromboembolic Pulmonary Hypertension: A Review of the Multifaceted Pathobiology.Biomedicines · 2023Review
- A Long-Term Follow-Up Study in Immune-Mediated Thrombotic Thrombocytopenic Purpura: What Are the Outcomes?Journal of clinical medicine · 2023Article
- Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension.Respiratory research · 2023Article
- Clinical Manifestations, Current and Future Therapy, and Long-Term Outcomes in Congenital Thrombotic Thrombocytopenic Purpura.Journal of clinical medicine · 2023Review
- Novel Classification of Thrombotic Disorders Based on Molecular Hemostasis and Thrombogenesis Producing Primary and Secondary Phenotypes of Thrombosis.Biomedicines · 2022Review
- Article
- Role of von Willebrand factor in venous thromboembolic disease.JVS-vascular science · 2022Review
- The Intriguing Relationships of von Willebrand Factor, ADAMTS13 and Cardiac Disease.Journal of cardiovascular development and disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 12 institutions in 6 countries.
Michael NewnhamDept of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Kieron SouthCentre for Haematology, Imperial College London, London, UK.
Marta BledaDept of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
William R AugerUniversity of California, San Diego, CA, USA.
Joan A BarberàHospital Clínic - IDIBAPS-CIBER Enfermedades Respiratorias, University of Barcelona, Barcelona, Spain.
Harm BogaardVU University Medical Centre, Amsterdam, The Netherlands.
Katherine BunclarkRoyal Papworth Hospital, Cambridge, UK.
John E CannonRoyal Papworth Hospital, Cambridge, UK.
Marion DelcroixKU Leuven - University of Leuven, Leuven, Belgium.ORCID 0000-0001-8394-9809
Charaka HadinnapolaDept of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Luke S HowardHammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
David JenkinsRoyal Papworth Hospital, Cambridge, UK.
Eckhard MayerKerckhoff Heart and Lung Centre, Bad Nauheim, Germany.
Choo NgRoyal Papworth Hospital, Cambridge, UK.
Christopher J RhodesCentre for Pharmacology and Therapeutics, Dept of Medicine, Hammersmith Campus, Imperial College London, London, UK.
Nicholas ScreatonRoyal Papworth Hospital, Cambridge, UK.
Karen ShearesRoyal Papworth Hospital, Cambridge, UK.
Michael A SimpsonDept of Medical and Molecular Genetics, King's College London School of Basic and Medical Biosciences, London, UK.
Mark SouthwoodRoyal Papworth Hospital, Cambridge, UK.
Li SuMRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Dolores TaboadaRoyal Papworth Hospital, Cambridge, UK.
Matthew TraylorDept of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Richard C TrembathDept of Medical and Molecular Genetics, King's College London School of Basic and Medical Biosciences, London, UK.
Sofia S VillarMRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Martin R WilkinsCentre for Pharmacology and Therapeutics, Dept of Medicine, Hammersmith Campus, Imperial College London, London, UK.
John WhartonCentre for Pharmacology and Therapeutics, Dept of Medicine, Hammersmith Campus, Imperial College London, London, UK.
Stefan GräfDept of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.ORCID 0000-0002-1315-8873
Joanna Pepke-ZabaRoyal Papworth Hospital, Cambridge, UK.
Michael LaffanCentre for Haematology, Imperial College London, London, UK.
David A LaneCentre for Haematology, Imperial College London, London, UK.
Nicholas W MorrellDept of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Mark ToshnerDept of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Papworth Hospital · GBUniversity of Cambridge · GBHammersmith Hospital · GBImperial College London · GBKing's College London · GBAmsterdam UMC Location Vrije Universiteit Amsterdam · NLCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESImperial College Healthcare NHS Trust · GBKerckhoff Klinik · DEKU Leuven · BENational Health Service · GBUniversity of California San Diego · US
Funding
British Heart Foundation FS/15/59/31839British Heart Foundation PG/11/50/28984British Heart Foundation SP/12/12/29836Medical Research Council MC_UU_00002/3Medical Research Council MR/K020919/1
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is an important consequence of pulmonary embolism that is associated with abnormalities in haemostasis. We investigated the ADAMTS13-von Willebrand factor (VWF) axis in CTEPH, including its relationship with disease severity, inflammation,
Indexed as
ADAMTS13 ProteinAdultAgedAged, 80 and overBiomarkersCase-Control StudiesChronic DiseaseEndarterectomyFemaleHumansHypertension, PulmonaryLinear ModelsMaleMiddle AgedMultivariate AnalysisPulmonary EmbolismADAMTS13 ProteinADAMTS13 protein, humanBiomarkersvon Willebrand Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.